MedTrace Logo

Teriflunomide Tecfidera LMCE

NCT03526224 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 120

Last updated 2021-01-06

No results posted yet for this study

Summary

This study will investigate the effect of teriflunomide in reducing cortical gray matter (CGM) atrophy and leptomeningeal (LM) inflammation over 24 months compared to dimethyl fumarate (Tecfidera®)

Conditions

  • Tecfidera
  • Teriflunomide

Interventions

DRUG

Dimethyl Fumarate

Individuals with MS treated with dimethyl fumarate (Tecfidera)

DRUG

Teriflunomide

Individuals with MS treated with teriflunomide (Aubagio)

Sponsors & Collaborators

  • University at Buffalo

    lead OTHER

Eligibility

Min Age
18 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2018-06-14
Primary Completion
2019-07-10
Completion
2019-07-10
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03526224 on ClinicalTrials.gov